Sanders Capital LLC Decreases Holdings in Elevance Health, Inc. $ELV

Sanders Capital LLC trimmed its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 1.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,768,918 shares of the company’s stock after selling 56,290 shares during the period. Elevance Health comprises approximately 2.3% of Sanders Capital LLC’s investment portfolio, making the stock its 14th largest holding. Sanders Capital LLC owned 2.60% of Elevance Health worth $1,864,053,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Regal Investment Advisors LLC purchased a new stake in Elevance Health during the third quarter worth about $3,502,000. Benchmark Investment Advisors LLC bought a new stake in Elevance Health in the third quarter worth about $390,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its stake in Elevance Health by 120.3% in the third quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 78,472 shares of the company’s stock valued at $25,356,000 after acquiring an additional 42,847 shares during the last quarter. Baupost Group LLC MA grew its position in shares of Elevance Health by 114.1% during the 3rd quarter. Baupost Group LLC MA now owns 1,319,000 shares of the company’s stock valued at $426,195,000 after acquiring an additional 703,000 shares during the period. Finally, GeoWealth Management LLC grew its position in shares of Elevance Health by 199.3% during the 3rd quarter. GeoWealth Management LLC now owns 4,998 shares of the company’s stock valued at $1,615,000 after acquiring an additional 3,328 shares during the period. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Up 1.3%

Shares of NYSE:ELV opened at $291.69 on Friday. The firm has a fifty day moving average price of $338.25 and a two-hundred day moving average price of $334.11. The company has a market cap of $64.38 billion, a price-to-earnings ratio of 11.61, a PEG ratio of 1.59 and a beta of 0.51. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $458.75.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be issued a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is 27.39%.

Wall Street Analyst Weigh In

ELV has been the topic of a number of research reports. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Royal Bank Of Canada lowered Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective for the company. in a report on Tuesday, February 3rd. Robert W. Baird raised their target price on Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $332.00 target price on shares of Elevance Health in a research note on Thursday, January 29th. Finally, Morgan Stanley cut their price target on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 17th. Twelve investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $387.40.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.